English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
Selecting appropriate first line lung cancer therapy
AACR 2009
18 - 22 Apr 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
8 Jul 2009
Views:
15791
Rating:
Save
Rate video
Dr Paul Bunn - University of Colorado, Denver, USA
erlotininb, cetuximab or gefitinib for lung cancer in pill form- less toxic and better tolerated, better survival for patients with EGFR gene mutation.
Categories:
Lung & pleura
Biology
Targeted molecules
Related Videos
The role of multidisciplinary tumour board in managing stage 3 lung cancer
Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland
1 Feb 2023
ESMO 2022: Lung roundup
Dr Luis Raez - Memorial Cancer Institute, Miami, USA
4 Oct 2022
From clinic to practice in NSCLC patients with exon 20 mutations
Prof Nicolas Girard - Institut Curie, Paris, France
13 Sep 2022
Pembrolizumab plus chemo shows prolonged OS and PFS improvement vs chemo for...
Dr Silvia Novello - University of Turin, Turin, Italy
11 Sep 2022
Scientists discover mechanism of action and an actionable inflammatory axis for...
Prof Charles Swanton - The Francis Crick Institute, London, UK
10 Sep 2022
WCLC 2022: Highlights
Dr Luis Raez - Memorial Cancer Institute, Florida, USA
31 Aug 2022
OncoAlert and ecancer weekly round up for August 8th - 14th, 2022
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
15 Aug 2022
What's new in molecular targeted treatments for EGFR mutant NSCLC
Dr Keith Kerr, Dr Melina Marmarelis, Prof Amanda Tufman and Dr Jordi Remón Masip
12 Aug 2022
Topics under discussion at the WCLC 2022 presidential symposium
Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain
9 Aug 2022
More from
e
cancer